Compare Digital Realty Trust, Inc. (DLR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs TG Therapeutics Inc — how do they compare? Digital Realty Trust, Inc. trades at $178.76 (market cap $65.32B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Digital Realty Trust, Inc. is far larger — about 8× TG Therapeutics Inc's market cap, and Digital Realty Trust, Inc. pays a 2.77% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Digital Realty Trust, Inc. for 93 Days and TG Therapeutics Inc for 16 Days on average.
| DLR | TGTX | |
|---|---|---|
Market Cap | $65.32B | $8.16B |
Volume | 2,563,950 | 1,735,121 |
Sector | Real Estate | Health |
52-Week High | $203.91 | $59.06 |
52-Week Low | $147.93 | $26.94 |
Typical Hold Time | 93 Days | 16 Days |
Enterprise Value | $84.03B | $8.37B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Digital Realty (DLR) trades at $176.07, down 2.44% today, amid bearish technical signals but strong fundamental momentum. The data center REIT shows robust revenue growth, with Q2 2026 EPS beating expectations by 150%, and benefits from AI-driven demand, evidenced by a record $1.9B backlog and 25.4% cash rent growth. Analyst consensus remains strongly bullish with a $222.35 price target, though technical indicators signal near-term weakness with support at $173.
DLR presents a compelling long-term opportunity driven by AI infrastructure expansion and strong leasing activity, but faces risks from high valuation (P/E 85.89) and capital-intensive growth. Investors should weigh the company's strategic positioning against execution risks and debt levels, with the current dip potentially offering entry points for growth-oriented portfolios.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
